DK2930245T3 - Cellelinje og fremgangsmåder til forbedret glycoproteinsialylering - Google Patents

Cellelinje og fremgangsmåder til forbedret glycoproteinsialylering Download PDF

Info

Publication number
DK2930245T3
DK2930245T3 DK15163041.5T DK15163041T DK2930245T3 DK 2930245 T3 DK2930245 T3 DK 2930245T3 DK 15163041 T DK15163041 T DK 15163041T DK 2930245 T3 DK2930245 T3 DK 2930245T3
Authority
DK
Denmark
Prior art keywords
cell line
sialidase
acid sequence
cells
expression
Prior art date
Application number
DK15163041.5T
Other languages
English (en)
Inventor
Min Zhang
James S Ross
Original Assignee
Sigma Aldrich Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Aldrich Co Llc filed Critical Sigma Aldrich Co Llc
Application granted granted Critical
Publication of DK2930245T3 publication Critical patent/DK2930245T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Claims (14)

1. Cellelinje, hvor cellelinjen omfatter forstyrret ekspression af mindst én kromosomalt integreret nukleinsyresekvens, der koder for en plasmamembran-associeret sialidase, hvis aminosyresekvens er mindst 90 % identisk med SEQ ID NO: 4.
2. Cellelinje ifølge krav 1, hvor aminosyresekvensen af den plasmamembran-associerede sialidase er mindst 95 % identisk med SEQ ID NO: 4.
3. Cellelinje ifølge krav 1 eller krav 2, hvor aminosyresekvensen af den plasmamembran-associerede sialidase består af SEQ ID NO: 4.
4. Cellelinje ifølge et hvilket som helst krav 1-3, der endvidere omfatter forstyrret ekspression af en kromosomalt integreret nukleinsyresekvens, der koder for en lysosomal sialidase, hvis aminosyresekvens er mindst 97 % identisk med SEQ ID NO: 2.
5. Cellelinje ifølge krav 4, hvor aminosyresekvensen af den lysosomale sialidase består af SEQ ID NO: 2.
6. Cellelinje ifølge krav 4 eller krav 5, hvor ekspressionen af den nukleinsyresekvens, der koder for den lysosomale sialidase er forstyrret af en teknik, der er udvalgt fra gruppen bestående af RNA-interferens, homolog rekombination og stedsspecifik rekombination.
7. Cellelinje ifølge et hvilket som helst krav 1-6, hvor ekspression af den nukleinsyresekvens, der koder for den plasmamembran-associerede sialidase er afbrudt af en teknik, der er udvalgt fra gruppen bestående af RNA-interferens, homolog rekombination og stedsspecifik rekombination.
8. Cellelinje ifølge krav 6 eller krav 7, hvor RNA-interferens (RNAi) er medieret af et RNAi-middel, der er udvalgt fra gruppen bestående af kort interfererende RNA, et kort håmål-RNA og en RNAi-ekspressionsvektor.
9. Cellelinje ifølge et hvilket som helst af de foregående krav, hvor cellelinjen er udvalgt fra gruppen bestående af en insektcellelinje, en pattedyrecellelinje, en gnavercellelinje, en ikke-human primatcellelinje og en human cellelinje.
10. Cellelinje ifølge krav 9, hvor cellelinjen er en kinesisk hamsterovarie- (CHO) cellelinje.
11. Fremgangsmåde til fremstilling af et glycoprotein, hvilken fremgangsmåde omfatter ekspression af en nukleinsyresekvens, der koder for glycoproteinet i en celle af en cellelinje ifølge et hvilket som helst af de foregående krav, hvor glycoproteinet har øget sialylering i forhold til en egnet kontrol.
12. Fremgangsmåde ifølge krav 11, hvor den nukleinsyresekvens, der koder for glycoproteinet, er udvalgt fra gruppen bestående af at være kromosomalt integreret og være ekstrakromosomal.
13. Nukleinsyre, der koder for et polypeptid, hvis aminosyresekvens består af SEQ ID NO: 4.
14. Polypeptid, hvis aminosyresekvens består af SEQ ID NO: 4.
DK15163041.5T 2007-10-12 2008-10-13 Cellelinje og fremgangsmåder til forbedret glycoproteinsialylering DK2930245T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97948307P 2007-10-12 2007-10-12
EP08838267.6A EP2195444B9 (en) 2007-10-12 2008-10-13 Cell line and methods for improved glycoprotein sialylation

Publications (1)

Publication Number Publication Date
DK2930245T3 true DK2930245T3 (da) 2017-12-18

Family

ID=40549857

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15163041.5T DK2930245T3 (da) 2007-10-12 2008-10-13 Cellelinje og fremgangsmåder til forbedret glycoproteinsialylering
DK08838267.6T DK2195444T3 (da) 2007-10-12 2008-10-13 Cellelinie og fremgangsmåder til forbedret sialylering af glycoprotein.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK08838267.6T DK2195444T3 (da) 2007-10-12 2008-10-13 Cellelinie og fremgangsmåder til forbedret sialylering af glycoprotein.

Country Status (8)

Country Link
US (1) US8273723B2 (da)
EP (2) EP2930245B1 (da)
JP (2) JP2011500032A (da)
CN (1) CN101896616B (da)
AU (1) AU2008310583A1 (da)
CA (1) CA2702120C (da)
DK (2) DK2930245T3 (da)
WO (1) WO2009049284A2 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014513520A (ja) 2010-12-29 2014-06-05 シグマ−アルドリッチ・カンパニー、エルエルシー Ａｄｍｅおよび毒物学的プロセスに関与するタンパク質の乱された発現を有する細胞
CA2817765A1 (en) * 2011-01-06 2012-07-12 The Johns Hopkins University Method of production of recombinant glycoproteins with increased circulatory half-life in mammalian cells
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
BR112015015182B1 (pt) 2012-12-24 2023-12-26 Coagulant Therapeutics Corporation Variante polipeptídica isolada do fator vii, seu método de preparação e seu uso, e composições farmacêuticas e seus usos
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
JP6482546B2 (ja) * 2013-07-19 2019-03-13 ラリクス・バイオサイエンス・リミテッド・ライアビリティ・カンパニーＬａｒｉｘ Ｂｉｏｓｃｉｅｎｃｅ， Ｌｌｃ 二重対立遺伝子ノックアウトを生成するための方法および組成物
US11060083B2 (en) 2013-07-19 2021-07-13 Larix Bioscience Llc Methods and compositions for producing double allele knock outs
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
US20180334493A1 (en) 2015-11-19 2018-11-22 Shire Human Genetic Therapies, Inc. Recombinant human c1 esterase inhibitor and uses thereof
EP4008343A3 (en) * 2017-03-08 2022-08-24 University of Georgia Research Foundation Inc. Methods and compositions related to increased viral production
AU2020300680A1 (en) * 2019-07-03 2022-02-03 Palleon Pharmaceuticals Inc. Recombinant sialidases and methods of using the same
US20220356457A1 (en) * 2019-07-03 2022-11-10 Palleon Pharmaceuticals Inc. Recombinant human sialidases, sialidase fusion proteins, and methods of using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010260A1 (en) * 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US6562588B2 (en) * 1993-05-17 2003-05-13 Genentech, Inc. Sialidase and recombinant cell lines
ATE474925T1 (de) * 1993-05-17 2010-08-15 Genentech Inc Rekombinante cho zell sialidase
US6436687B1 (en) * 1999-04-22 2002-08-20 Virginia Commonwealth University cDNA sequence of mouse brain sialidase gene
US20030014493A1 (en) * 2001-07-13 2003-01-16 Sanyo Electric Co., Ltd. Linkage system for medical institutions
US20090203055A1 (en) * 2005-04-18 2009-08-13 Massachusetts Institute Of Technology Compositions and methods for RNA interference with sialidase expression and uses thereof
WO2007102432A1 (ja) * 2006-03-02 2007-09-13 Kyowa Hakko Kogyo Co., Ltd. 糖蛋白質組成物の製造方法

Also Published As

Publication number Publication date
EP2195444A4 (en) 2012-04-11
US20100291624A1 (en) 2010-11-18
EP2195444B9 (en) 2015-09-16
CA2702120A1 (en) 2009-04-16
WO2009049284A2 (en) 2009-04-16
EP2930245B1 (en) 2017-11-22
JP6068410B2 (ja) 2017-01-25
EP2195444A2 (en) 2010-06-16
EP2195444B1 (en) 2015-07-01
DK2195444T3 (da) 2015-08-24
EP2930245A1 (en) 2015-10-14
WO2009049284A3 (en) 2009-12-30
JP2015057059A (ja) 2015-03-26
JP2011500032A (ja) 2011-01-06
US8273723B2 (en) 2012-09-25
CA2702120C (en) 2016-05-17
AU2008310583A1 (en) 2009-04-16
CN101896616A (zh) 2010-11-24
CN101896616B (zh) 2014-06-04

Similar Documents

Publication Publication Date Title
DK2930245T3 (da) Cellelinje og fremgangsmåder til forbedret glycoproteinsialylering
Zhang et al. Enhancing glycoprotein sialylation by targeted gene silencing in mammalian cells
AU2005214904B2 (en) Anti-microRNA oligonucleotide molecules
KR101710487B1 (ko) 재조합 이듀로네이트-2-설파타제를 생산하는 세포
US20090203055A1 (en) Compositions and methods for RNA interference with sialidase expression and uses thereof
EP3137595B1 (en) Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest
EP2802654B1 (en) Production of recombinant proteins with simple glycoforms
JP2003524395A (ja) 細胞内シアリル化経路の操作
CN104119445A (zh) 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
WO2012082509A2 (en) Biomarkers for enhanced protein production
Barisone et al. Glycoproteins of the vitelline envelope of Amphibian oocyte: biological and molecular characterization of ZPC component (gp41) in Bufo arenarum
CN113661247A (zh) 细胞穿透转座酶
US20230210960A1 (en) New use of cmtr1 having sirna production and function enhancing activity
Chotwiwatthanakun et al. The ribophorin I from Penaeus monodon shrimp: cDNA cloning, expression and phylogenetic analysis
KR101873327B1 (ko) 애기 장대에서 유래한 신규 호밍 엔도뉴클레아제
WO2001042492A1 (en) Engineering intracellular sialylation pathways
WO2024206759A1 (en) Crispr nuclease polypeptides and gene editing systems comprising such
US20090221065A1 (en) Composition for suppressing the expression of fucosyltransferase
WO2023223219A1 (en) IMPROVED PROTEIN PRODUCTION USING miRNA TECHNOLOGY
WO2023173140A2 (en) Targeted delivery of armms
US9994813B2 (en) Role for the perlman syndrome exonuclease Dis3l2 in the Lin28-let-7 pathway
WO2005030948A1 (ja) ＲＮａｓｅＩＩＩ活性を有するポリペプチド
Olivera et al. On a Potential Global Role for Vitamin K-dependent y-Carboxylation in Animal Systems
JP2009284814A (ja) Ｏ−結合型ｎ−アセチルグルコサミン転移酵素及びその遺伝子